ScienceLife Sciences

Diagnosing Dx

Elevra Consulting

How do we transform cutting-edge scientific discoveries into life-saving diagnostics?

On Diagnosing Dx, we explore the scientific innovation driving diagnostics forward, unpack industry challenges, and spotlight success stories. Join us as we speak with leading researchers and innovators at the forefront of Dx.

Learn to:
🔹 Navigate industry challenges
🔹 Understand emerging science
🔹 Strategise for growth
🔹 Gain future-focused insight

Essential listening for everyone involved in bringing new sciences to life in the Dx and Omics industry, Subscribe now!

Play

Open in

32 episodes
weekly
Avg 40 min
English

Episodes 32

Newest Oldest Longest

All12 Unplayed12 In progress0 Played0

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.

May 28 · 46 min
The EU Market Access Playbook for Diagnostics Companies - Svetlana Nikic
In this episode of Diagnosing Dx, I’m joined by Svetlana Nikic, Founder of Precision Oncology Consulting.Svetlana shares her journey from Roche and Illumina into building her own consultancy focused on helping diagnostics companies navigate the realities of market access in Europe. We explore the gap between innovation and implementation, why strong science alone does not guarantee patient access, and what US diagnostics companies often underestimate when they look at Europe as a commercial opportunity.We also discuss what it really takes to make oncology diagnostics work across European markets, from KOL engagement and clinical utility studies to health economics, reimbursement strategy, and the complexity of regional healthcare systems. This is a practical conversation about precision oncology, policy, and why implementation may now matter more than innovation.Key takeaways:🔹 Why innovation without implementation does not create real patient impact🔹 What diagnostics companies need to understand before entering Europe🔹 Why clinical utility alone is often not enough for reimbursement in European markets🔹 How KOL engagement, local evidence, and health economics shape adoption🔹 Why diagnostics now needs more implementation focus and less innovation for innovation’s sakeGuest:Svetlana NikicLinkedIn: https://www.linkedin.com/in/svetlananikic/Host:David FilbyLinkedIn: https://www.linkedin.com/in/davidfilby/Chapters:01:50 Svetlana Nikic’s background in diagnostics and oncology07:37 What Precision Oncology Consulting helps companies do in Europe10:25 When diagnostics companies should start planning for Europe15:23 How reimbursement works across European markets19:22 Why KOL engagement is so important for market access20:57 Choosing the right European market and identifying low-hanging fruit25:28 Why the reimbursement bar is often higher in Europe43:30 Diagnostics in 2026: implementation, policy, and what needs to change next🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.#PrecisionOncology #Diagnostics #MarketAccess #Reimbursement #Europe #Oncology #BiomarkerTesting #healthcarepolicy #ClinicalUtility #HealthEconomics #CancerDiagnostics #LifeSciences #HealthCare #PrecisionMedicine #Innovation
May 19 · 45 min
The Future of Kidney Transplant Monitoring: Moving Beyond Biopsies - Sara Barrington, CEO of Verici Dx
In this episode of Diagnosing Dx, I’m joined by Sara Barrington, CEO at Verici Dx. Sara explains how Verici Dx is tackling one of the biggest unresolved problems in kidney transplant care: helping clinicians monitor patients more precisely after transplant without relying so heavily on biopsies and legacy testing. We explore why balancing rejection risk against unnecessary immunosuppression is so difficult, and how better molecular insight could support earlier, more accurate decisions. We also discuss Verici Dx’s RNA sequencing and AI-driven approach, the decision to license one test to Thermo Fisher while commercialising another directly, and what it means to build a diagnostics company that went public from day one. This is a practical conversation about transplant medicine, commercialization, and better clinical decision-making. Key takeaways: 🔹 Why post-transplant monitoring still relies too heavily on invasive and outdated methods 🔹 How RNA sequencing and AI could improve rejection prediction and patient management 🔹 Why reducing unnecessary immunosuppression is such an important clinical goal 🔹 How Verici Dx built an end-to-end transplant testing strategy across pre- and post-transplant care 🔹 What licensing, reimbursement, and public-market strategy look like in a real diagnostics company Guest: Sara Barrington CEO at Verici Dx LinkedIn: https://www.linkedin.com/in/sara-barrington-06926382/ Host: David Filby LinkedIn: https://www.linkedin.com/in/davidfilby/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.
May 7 · 44 min
How Cleveland Diagnostics Is Redefining Prostate Cancer Testing
In this episode of Diagnosing Dx, I’m joined by Arnon Chait, PhD, MBA, Chief Innovation Officer at Cleveland Diagnostics.Arnon shares his journey from NASA physicist to diagnostics innovator, and explains how Cleveland Diagnostics tackled one of the biggest challenges in prostate cancer testing: turning a widely used but flawed marker like PSA into something more clinically useful. We explore the role of protein structure and biomarkers in disease, why so many diagnostics fall short after the science is proven, and what it means to build from real clinical need rather than lab-first thinking.We also discuss the road from development to commercialization, the realities of regulatory strategy and FDA approval, and where diagnostics could be heading next as AI and new technologies reshape disease detection. This is a practical conversation about what it really takes to make diagnostics work in the real world.Key takeaways:🔹 Why strong science alone is not enough to build a successful diagnostic🔹 How Cleveland Diagnostics rethought prostate cancer testing beyond traditional PSA🔹 Why clinical utility, adoption, and reimbursement matter as much as validation🔹 What Arnon learned moving from physics and space science into diagnostics🔹 How AI and new technologies could shape the future of disease detectionGuest:Arnon Chait, PhD, MBAChief Innovation Officer, Cleveland DiagnosticsLinkedIn: https://www.linkedin.com/in/arnonchait/ Host:David FilbyFounder & CEO, Elevra ConsultingLinkedIn: https://www.linkedin.com/in/davidfilby/Chapters:00:00 Introduction and background03:56 Transition from NASA to diagnostics06:48 Lessons from NASA applied to diagnostics09:40 Founding Cleveland Diagnostics and developing the prostate cancer test15:52 Clinical challenges in prostate cancer18:31 Commercialization and FDA approval21:53 Future of Cleveland Diagnostics and the impact of AI27:22 Market outlook, industry changes, and lessons learned🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.#Diagnostics #ProstateCancer #Biotech #Biomarkers #Proteomics #PrecisionMedicine #MedicalDiagnostics #HealthcareInnovation #DiseaseDetection #MolecularDiagnostics #ClinicalUtility #AIinHealthcare #CancerDiagnostics #LifeSciences #DiagnosingDx
April 29 · 47 min
From Single Cell to Atera: The Future of Biology Measured at Scale - Serge Saxonov, Co-founder & CEO of 10x Genomics
In this episode of Diagnosing Dx, I’m joined by Serge Saxonov, Co-founder and CEO of 10x Genomics, a leader in single cell and spatial biology. Serge shares the story behind 10x Genomics, the evolution of its foundational technologies, and the launch of Atera, a new platform designed to enable whole transcriptome analysis in tissue at scale with single cell level sensitivity. We explore why biology has been fundamentally limited by the way we measure it, what changes when those constraints are removed, and how better tools can open up entirely new possibilities for discovery and precision medicine. We also discuss the intersection of AI and biology, the challenge of translating research tools into clinical impact, and what it takes to build and scale a category-defining company in life sciences. From innovation and platform thinking to talent, culture, and the future of biotech, this is a practical conversation about how the next generation of biology tools could shape healthcare. Key takeaways: 🔹 How 10x Genomics helped define the single cell and spatial biology category 🔹 Why better measurement tools can fundamentally change what is possible in biology 🔹 How AI and biology together could accelerate discovery and precision medicine 🔹 Why most research technologies never make it into the clinic 🔹 What skills, culture, and execution will matter most in biotech over the next decade Guest: Serge Saxonov Co-founder and CEO, 10x Genomics LinkedIn: https://www.linkedin.com/in/serge-saxonov-7b42572/ Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: www.linkedin.com/in/davidfilby/ Key chapters: 00:00 Introduction and background of Serge Saxonov 14:32 The birth of 10x Genomics 25:54 The future of disease understanding and diagnostics 28:09 Evolution of 10x Genomics and market fit 34:25 Building culture, talent, and innovation at scale 38:27 Skills for the future in the age of AI 40:47 The convergence of AI and biology for precision medicine 46:51 Future directions for 10x Genomics and new technologies 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.
April 27 · 41 min
True At-Home Diagnostics: Reshaping Infectious Disease with Nathalya Mamane, CEO of Anywhere Dx
In this episode of Diagnosing Dx, I’m joined by Nathalya Mamane, Co-Founder and CEO at Anywhere Dx. Nathalya shares the origin story behind Anywhere Dx and how a personal pain point led her to build a diagnostics company focused on bringing molecular testing into the home. We explore why the current standard of care for infectious disease testing is still too slow, too expensive, and too dependent on centralised infrastructure, and what COVID revealed about how people actually want to engage with diagnostics when access and convenience matter most. We also discuss what it really takes to build an at-home diagnostic that can scale, from creating a fully disposable, instrument-free molecular platform to navigating regulatory validation, strategic partnerships, and the commercial realities of diagnostics today. This is a practical conversation about access, simplicity, and what it means to design diagnostics for real consumer use rather than idealised clinical workflows. Key takeaways: 🔹 Why most at-home diagnostics still fall short on simplicity and scalability 🔹 How Anywhere Dx is approaching low-cost, disposable molecular testing 🔹 Why strategic partnerships are critical for commercialising diagnostics effectively 🔹 What COVID revealed about consumer behaviour and diagnostic access 🔹 Why funding, validation, and regulatory strategy remain major hurdles in diagnostics Guest: Nathalya Mamane LinkedIn: www.linkedin.com/in/nathalya-mamane/ Learn more about Anywhere Dx: https://www.anywhere.health/ Host: David Filby LinkedIn: www.linkedin.com/in/davidfilby/ Learn more about Elevra Consulting: https://elevraconsulting.com/ Key chapters: 01:48 Nathalya’s journey into diagnostics 03:38 The birth of Anywhere Dx 07:54 Technology and product overview 10:45 Market need, strep, and the impact on healthcare systems 14:44 Science behind the product 19:41 Development status and funding challenges 26:19 Commercial strategy, partnerships, and regulatory pathway 30:18 Investor sentiment and market outlook 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.
April 22 · 40 min
The New Rules of Diagnostics: Lean Teams, Faster Revenue, Smarter Growth - MJ Hymes, i5 BioPartners
In this episode of Diagnosing Dx, I’m joined by MJ Hymes, Managing Partner at i5 BioPartners. MJ shares his journey from molecular biology into the commercial side of life sciences, and explains why great science alone is rarely enough to build a successful diagnostics or biotech company. We explore the gap between innovation and execution, why so many early-stage companies struggle to turn promising technology into real traction, and how the funding landscape has shifted for founders building today. We also discuss what it takes to get a life sciences company market-ready, from building leaner models earlier on to navigating commercialization, fundraising, and strategic support at the right time. From AI and multiomics to emerging technologies in diagnostics and drug discovery, this is a practical conversation about turning early-stage science into a real business. Key takeaways: 🔹 Why strong science alone is not enough to build a successful company 🔹 How early-stage biotech and diagnostics teams should think about commercialization sooner 🔹 Why product-market fit matters earlier than many founders realise 🔹 How the funding environment is changing for pre-seed to Series A companies 🔹 What makes a pitch deck, investor process, and go-to-market strategy more effective Chapters: 00:00 Introduction and background of MJ Hymes 03:26 Transitioning from science to commercialization 06:16 The formation of i5 Bio Partners 09:41 Market trends and outsourcing in life sciences 12:20 Supporting early-stage companies and revenue generation 18:15 Exciting developments in life sciences 21:21 Common gaps in early-stage companies 24:36 Fundraising strategies, pitch decks, and market insights 30:39 Establishing product-market fit 33:33 Future plans for i5 Bio Partners Guest: MJ Hymes LinkedIn: https://www.linkedin.com/in/matthewhymes Host: David Filby LinkedIn: https://www.linkedin.com/in/davidfilby/ Resources mentioned: BioTools Innovator Program - https://biotoolsinnovator.com/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.
April 15 · 48 min
“Wait and Watch” Is Failing Cancer Patients — Harbinger Health on What Comes Next
In this episode of Diagnosing Dx, I’m joined by Ajit Singh, CEO at Harbinger Health.Ajit has spent decades building, scaling, and investing in diagnostics companies, and this conversation draws on that full perspective. We explore why cancer diagnosis remains one of the biggest unresolved problems in care, what happens after suspicion enters the system, and why so many patients still face delays, uncertainty, and fragmented pathways before they get answers.Ajit explains how Harbinger Health is approaching this challenge, not by competing directly with existing screening models, but by helping define a new category focused on resolving ambiguity earlier and more effectively. We also discuss what it takes to build in diagnostics today: operational agility, leadership transitions, stakeholder complexity, commercialisation strategy, and the capital landscape shaping biotech in 2026.This is one of the most important conversations we’ve had on Diagnosing Dx, a practical look at what separates diagnostics companies that launch from those that actually scale.Key takeaways:🔹 Why healthcare innovation depends on nimbleness, not just process🔹 What it takes to build a new category in cancer detection🔹 Why leadership needs to evolve as a diagnostics company grows🔹 How strong positioning and ecosystem leverage can shape fundraising success🔹 Why stakeholder complexity is one of the biggest barriers to adoptionKey chapters:00:00 Introduction to diagnostics, capital, and the market landscape03:57 Ajit Singh’s career journey and lessons from Siemens10:02 Moving from corporate leadership to startup life12:57 Harbinger Health and the challenge of cancer diagnosis18:48 Building a new category in cancer detection23:52 Early testing, commercialization, and market adoption30:52 Leadership transition, company growth, and scaling33:15 Venture capital, funding, and future growth strategy37:08 Navigating complexity in healthcare and the role of mentorship43:06 Future milestones, product launches, and the capital landscapeGuest:Ajit SinghCEO, Harbinger Health LinkedIn: https://www.linkedin.com/in/ajit-singh-flagship/ Host: David FilbyCEO, Elevra ConsultingLinkedIn: https://www.linkedin.com/in/davidfilby/🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.
April 8 · 36 min
Women Wait 11 Years for a Diagnosis, Endometrics Are Changing That - Yana Aznavour
This week I’m joined by Yana Aznavour, MD, PhD, OB-GYN surgeon and Founder & CEO of Endometrics. We unpack one of the biggest failures in modern healthcare: why women are still waiting up to 11 years for an endometriosis diagnosis, why the current standard still relies on surgery, and what it takes to build a diagnostic that clinicians will actually trust and use. This conversation goes beyond the science. We also explore why so many diagnostics fail at the point of adoption, what founders consistently get wrong when bringing new tests to market, and why evidence, workflow fit, and clinical credibility matter just as much as innovation itself. Key takeaways: 🔹 Why endometriosis diagnosis still takes years for so many women 🔹 How a non-invasive diagnostic could change the standard of care 🔹 Why trust, evidence, and workflow fit determine whether a test gets adopted 🔹 What founders often miss when building and commercialising diagnostics Chapters: 00:00 Introduction to Yana Aznavour and Endometrics 03:45 Transition from Clinical Practice to Entrepreneurship 06:51 The Vision Behind Endometrics 09:49 Recent Achievements and Recognition 12:52 Understanding the Unmet Needs in Women's Health 15:58 Current Status and Future Plans for Endometrics 19:00 Challenges and Opportunities in the Diagnostics Market 22:00 The Importance of Clinical Impact in Innovation 25:04 Building a Strong Team and Advisory Board 27:53 Future Directions and Expanding the Platform Resources mentioned: RADx® Tech ACT ENDO Challenge (NIH) - https://www.nichd.nih.gov/research/supported/challenges/radx-tech-endometriosis PMWC Conference - https://pmwcintl.com/ Health Equity Business Accelerator (Blue Cross Blue Shield of Massachusetts / MassChallenge) - https://masschallenge.org/heba-2026/ Berkeley SkyDeck Fund - https://skydeck.vc/ Granatus Ventures - https://www.granatusventures.com/ Supernode Ventures - https://www.supernode.vc/ First Spark Ventures - https://www.firstsparkventures.com/ Guest: Yana Aznavour, MD, PhD LinkedIn: https://www.linkedin.com/in/yana-aznavour-md/ Host: David Filby LinkedIn: https://www.linkedin.com/in/davidfilby/ Diagnosing WDx is a sister series from Diagnosing Dx, hosted by Elevra Consulting, spotlighting the gaps, opportunities, and innovations shaping the future of women’s diagnostics. Learn more about Elevra Consulting: https://elevraconsulting.com/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
March 31 · 42 min
Finding Lung Cancer Before It’s Too Late: From Uncertainty to Action
In this episode of Diagnosing Dx, I’m joined by Maria Zannes, Chief Executive Officer and Director at bioAffinity Technologies. Maria shares her journey from journalism and business leadership into diagnostics, and explains how bioAffinity Technologies is building a non-invasive platform for lung disease diagnosis, starting with early lung cancer detection. We explore the limitations of current pathways for indeterminate pulmonary nodules, how CyPath Lung is designed to support faster, more confident decision-making, and why earlier detection can have such a major impact on outcomes. We also discuss what it really takes to build and scale in diagnostics, from clinical validation and workflow adoption to balancing commercialization with continued innovation. From lung cancer screening and clinical trials to asthma, COPD, and future opportunities in the platform, this is a practical conversation about bringing meaningful diagnostic advances to market. Key takeaways: 🔹 Why early detection remains one of the biggest opportunities in lung cancer care 🔹 How non-invasive testing could improve patient comfort and clinical decision-making 🔹 Why strong science, clinical validation, and commercial execution all matter in diagnostics 🔹 How bioAffinity Technologies is balancing commercialization with continued discovery and innovation 🔹 What the company’s upcoming military and VA clinical trial could mean for wider adoption Chapters: 00:00 Introduction 02:24 Why Texas is becoming a hub for diagnostics companies 02:58 Maria Zannes’ background and the origins of bioAffinity Technologies 05:42 Personal motivation, team building, and the role of science in innovation 09:27 bioAffinity’s platform technology and how CyPath Lung works 11:31 Early lung cancer detection, screening awareness, and non-invasive testing 16:25 Commercial strategy, test performance, and real-world use cases 20:02 Team growth, company milestones, and the journey to commercialization 23:27 Clinical validation, the upcoming military and VA trial, and the economic case for CyPath Lung 31:36 Company setup, future growth, therapeutic potential, and what’s next Guest: Maria Zannes LinkedIn: https://www.linkedin.com/in/maria-zannes-32496815/ Host: David Filby LinkedIn: https://www.linkedin.com/in/davidfilby/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.
March 24 · 42 min
Scaling Precision Medicine: Faster Reports, Smarter Trials, Better Care - Garreth Hippe at GenomOncology
In this episode of Diagnosing Dx, I’m joined by ⁠Garreth Hippe⁠, Chief Commercial Officer at ⁠GenomOncology⁠, a software company helping turn complex genomic data into faster, more actionable decisions in oncology. Garreth has spent much of his career in clinical genomics, bioinformatics, and healthcare software, and in this conversation we explore how the field has evolved over the last 20 years, from far slower sequencing workflows to a point where whole genomes can now be analysed in clinically meaningful timeframes. We also unpack how GenomOncology is helping labs bring genomic reporting in-house, reduce turnaround times, ease pressure on molecular pathologists, and match patients to relevant clinical trials before those opportunities are missed. A big part of the discussion focuses on AI, not as hype, but as a real force multiplier in healthcare software. Garreth shares how it is accelerating development, improving reporting workflows, and opening up new ways to work with clinical and omics data. We also discuss why genomics is still underused in parts of oncology, where adoption is heading next, and why whole genome sequencing could play a much bigger role in the future of cancer care. Key takeaways: 🔹 How software is helping translate genomic complexity into clinical action 🔹 Why clinical trial matching remains such a critical challenge in oncology 🔹 Where AI could have the biggest impact across precision medicine 🔹 Why whole genome sequencing may define the future of cancer care Chapters: 00:00 Introduction 01:56 Garreth Hippe’s background in clinical genomics and software 03:04 What clinical genomics means: somatic vs germline testing 05:28 How software in genomics has evolved over the last 20 years 07:14 AI in healthcare and precision medicine 09:34 What GenomOncology does and where it fits in the oncology workflow 15:14 How AI is accelerating product development and lean growth 20:21 The core problems GenomOncology is solving in reporting and clinical trial matching 26:10 Company progress, product development, and commercial milestones 33:46 Adoption challenges in genomics and the future of whole genome sequencing 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.
March 12 · 48 min
The Women’s Health Data Gap: Why Diagnostics Are Decades Behind - Marra Francis, MD
In this first episode of Diagnosing WDx, the new women’s health-focused sister series from Diagnosing Dx, I’m joined by Marra Francis, MD, board-certified OB-GYN, women’s health expert, and advisor to multiple early-stage diagnostics companies. Recorded in the week of International Women’s Day, this conversation explores one of the biggest blind spots in healthcare: the historic and ongoing gap in women’s diagnostics. Marra breaks down why women were excluded from clinical trials for decades, why many diagnostics and therapeutics still used today were originally studied in men, and why conditions like preeclampsia remain dangerously under-researched. We also explore the role of startups, investors, and AI in helping close the data gap and drive a new era of innovation in women’s health. If Diagnosing Dx shines a light on the diagnostics industry, Diagnosing WDx shines a light on the women it has overlooked for far too long. Key takeaways: 🔹 Why women were historically excluded from clinical research 🔹 How gaps in data still affect diagnostics and therapeutics today 🔹 Why preeclampsia and autoimmune disease expose major weaknesses in women’s health research 🔹 The investment gap holding back progress in women’s diagnostics 🔹 Where AI, startups, and new research models could help move the field forward Chapters: 00:00 Introduction 01:02 Welcome to Diagnosing WDx 01:53 Marra’s background and path into women’s health diagnostics 04:49 The real diagnostic gaps women face in clinical practice 08:05 Marra’s work across women’s health startups and innovation 11:11 Consumer health, trust, and access to testing 17:13 The history of women’s exclusion from clinical trials 20:10 Preeclampsia, autoimmune disease, and the real-world impact of the data gap 25:41 Why progress in women’s health is still not moving fast enough 29:22 Diagnostics tested in men and what that means for women today 32:59 Can AI help close the women’s health data gap? 42:10 What needs to change next in women’s diagnostics 47:47 Why Diagnosing WDx matters Guest: Marra S. Francis LinkedIn: https://www.linkedin.com/in/marrasfrancis/ Resources mentioned: 1. Women’s Health Initiative 2. MIT Catalyst Program 3. For You and Me (FYM) 4. Nobel Prize in Medicine and Physiology Diagnosing WDx is a sister series from Diagnosing Dx, hosted by Elevra Consulting, spotlighting the gaps, opportunities, and innovations shaping the future of women’s diagnostics. Learn more: https://elevraconsulting.com/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
February 17 · 42 min
The $4 Billion Problem in Lyme Diagnostics with Aces Diagnostics
In this episode of Diagnosing Dx, I’m joined by ⁠Tammy Crawford⁠, Chief Executive Officer, and ⁠Holly Ahern⁠, Chief Scientific Officer at ⁠Aces Diagnostics⁠, a company building what could become the first highly accurate test across all stages of Lyme disease. We explore why early Lyme is so often missed, the myth of the bullseye rash, and the structural gaps in today’s testing pathway. Tammy and Holly explain how their personal experiences shaped Aces Diagnostics’ mission and how they’re approaching the problem with a more rigorous, data-driven framework built for real-world adoption. This conversation is a grounded look at what it takes to restore confidence in infectious disease diagnostics and why more reliable testing could transform both patient outcomes and healthcare economics. Key takeaways: 🔹 Why current Lyme diagnostics frequently miss early-stage disease 🔹 How combining multiple biomarkers improves diagnostic accuracy 🔹 The role of machine learning in interpreting complex immune signatures 🔹 Why FDA approval is essential for trust, adoption, and scale 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.

Showing 21–32 of 32 episodes